Orchard Therapeutics

Bobby Gaspar, M.D., Ph.D., CEO
London, UK
(NASDAQ: ORTX)
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families, and caregivers is immense and current treatment options are limited or do not exist.
www.orchard-tx.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions